Clinical Trials Logo

Colorectal Cancer Recurrent clinical trials

View clinical trials related to Colorectal Cancer Recurrent.

Filter by:
  • None
  • Page 1

NCT ID: NCT06314971 Recruiting - Colorectal Cancer Clinical Trials

Predicting Local and Distant Recurrence in T1 Colorectal Cancer

T1CR
Start date: March 15, 2023
Phase:
Study type: Observational

Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC. This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC.

NCT ID: NCT06314958 Recruiting - Colorectal Cancer Clinical Trials

Stage II/III Colorectal Cancer Recurrence

CENSURE
Start date: March 15, 2023
Phase:
Study type: Observational

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

NCT ID: NCT06271980 Completed - Colorectal Cancer Clinical Trials

Early-Onset Colorectal Cancer Recurrence

ENCORE
Start date: April 15, 2023
Phase:
Study type: Observational

Survivors of early-onset colorectal cancer (diagnosed before age 50) may experience colorectal cancer recurrence several years after curative-intent treatments, but clinical guidelines provide unclear guidance on endoscopic surveillance. This study aims to predict recurrence-free survival and overall survival, in survivors of early-onset colorectal cancer, using a tumor-based molecular assay based on microRNA (ribonucleic acid)

NCT ID: NCT06229340 Recruiting - Lung Cancer Clinical Trials

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

N??-RAS
Start date: October 3, 2023
Phase: Phase 2
Study type: Interventional

There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the consequences of RAS activation is important for improving therapeutic outcomes for patients with refractory malignancies. The use of leflunomide or the combination of MEK inhibitor + hydroxychloroquine ± bevacizumab is promising for patients with mutations in RAS cascade genes who have failed all existing treatment standards.

NCT ID: NCT04368507 Completed - Clinical trials for Colorectal Cancer Metastatic

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

Start date: August 9, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics and antitumor activity of YYB101 with Irinotecan, patients who are metastatic or recurrent Colorectal Cancer Patients.

NCT ID: NCT04067986 Recruiting - Clinical trials for Colorectal Cancer Recurrent

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Start date: August 20, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The efficacy and safety of the use of Camrelizumab combined with Apatinib

NCT ID: NCT02390947 Completed - Clinical trials for Colorectal Cancer Metastatic

Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT)

FACT
Start date: January 2015
Phase: Phase 3
Study type: Interventional

Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, whose anti-tumor and anti-angiogenesis effects have been validated in preclinical tests. In PhaseⅡb study, a significantly improved Progression Free Survival (PFS) was found in patients with advanced colorectal cancer treated with Famitinib compared to placebo. On the other hand, the toxicity of Famitinib was manageable in both PhaseⅠand Ⅱb studies. The purpose of this study is to determine whether Famitinib can improve Overall Survival (OS) compared with placebo in total 540 patients with advanced colorectal cancer who have failed in previously received at least two lines of standard chemotherapy.

NCT ID: NCT01762293 Completed - Colorectal Cancer Clinical Trials

A Study of Famitinib in Patients With Advanced Colorectal Cancer

Start date: April 2012
Phase: Phase 2
Study type: Interventional

Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the toxicity is manageable. The purpose of this study is to determine whether Famitinib can improve progression free survival compared with placebo in patients with advanced colorectal cancer who failed in previous at least two lines of chemotherapy.